UNSPSC 51352009: Norethynodrel or noretynodrel

This classification denotes a therapeutic progestin with the molecular formula C20H26O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 88181ACA0M, chemically known as 19-norpregn-5(10)-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)- but generally known as norethynodrel, which bears US NIH Compound Identifier 4537. European Medicines Agency schedules Noretynodrel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12439MIG.

The term NORETYNODREL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). Norethynodrel or noretynodrel bears US NLM identifiers UMLS ID C0028360 and NCI Concept Code C66244. SMILES: CC12CCC3C(C1CCC2(C#C)O)CCC4=C3CCC(=O)C4.

UNSPSC 51352009 Norethynodrel or noretynodrel is a Commodity code covering oral contraceptive active pharmaceutical ingredients supplied to state and local government health programs. State and local procurement under this code focuses on generic multi-source pharmaceuticals and over-the-counter products distributed through cooperative purchasing alliances and authorized drug wholesalers to state agencies, counties, municipalities, and other public health facilities. The work involves manufacturers and repackagers supplying finished pharmaceutical products with specific National Drug Codes, maintaining current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance, and offering pricing through established wholesaler chargeback systems. Issuing bodies include state health departments, cooperative purchasing alliances, and public health authorities participating in multi-state procurement vehicles.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted the most recent relevant opportunity on January 20, 2026—a Request for Proposal (RFP) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products effective July 1, 2026, with proposals due March 26, 2026. The procurement requires vendors to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), maintain contractual relationships with at least two of the three, and demonstrate pricing flexibility through flat price, net price, or WAC-minus structures. The contract term is two years for new vendors with optional extensions, and evaluation weight is 75 percent price competitiveness, 10 percent fixed pricing for the contract term, and 15 percent combined administrative compliance and EDI capability. Insurance requirements include $5 million per-occurrence commercial general liability, $2 million network security and privacy liability, and $2 million professional liability. The opportunity spans Minnesota and Oregon; no specific dollar value or set-aside designation is disclosed.